A single-dose, dose-escalation study of subcutaneous daclizumab high-yield process in healthy volunteers.
Latest Information Update: 30 Oct 2017
Price :
$35 *
At a glance
- Drugs Daclizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics; Pharmacokinetics
- Acronyms 1015
- 01 Oct 2014 Results of integrated analysis intravenous and subcutaneous, single- and multiple- dose administration using patient data from CTPs 289783, 289782 and 289780 published in the Clinical Pharmacokinetics
- 01 Oct 2014 New trial record